ISIS up +2.94% percent Today $ISIS High is at 46.3
Post# of 115
Posted On: 11/10/2014 1:44:44 PM
ISIS up +2.94% percent Today $ISIS High is at 46.32 and the Low 44.01 with current volume of 1,069,752.
Recent News posted below.
Isis Pharmaceuticals ISIS other info.
http://investorshangout.com/Isis-Pharmaceuticals-ISIS-54504/
ISIS Isis Pharmaceuticals Recent Headline News
34.6% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Fri Nov 07, 4:40PM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 34.61% as of today's recent price of $44.59.
ISIS: 46.34 (+1.75)
Look for Shares of Isis Pharmaceuticals to Potentially Rebound after Yesterday's 1.46% Sell Off
Comtex SmarTrend(R) - Fri Nov 07, 4:09PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $42.06 to a high of $44.93. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $43.87 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ISIS: 46.34 (+1.75)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 325.92 (+5.17), ALNY: 98.81 (+2.97), ISIS: 46.34 (+1.75), OGXI: 2.18 (unch), TEVA: 58.04 (+0.34), RGLS: 22.80 (+0.72), GSK: 45.18 (+0.27), SNY: 46.26 (+0.57)
Isis beats 3Q profit forecasts
Automated Insights - Fri Nov 07, 7:48AM CST
CARLSBAD, Calif. (AP) _ Isis Pharmaceuticals Inc. (ISIS) on Friday reported a third-quarter loss of $26.7 million.
ISIS: 46.34 (+1.75)
Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
PR Newswire - Fri Nov 07, 7:30AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $13.4 million and $34.9 million for the three and nine months ended September 30, 2014, respectively, compared to an NOL of $22.7 million and $23.5 million for the same periods in 2013. Isis' revenue increased by more than 20% during the first nine months of 2014 compared to 2013 primarily due to the successes of its partnered programs as they advanced through research and development. In addition to the increase in revenue, Isis had a planned increase in operating expenses primarily associated with its late-stage clinical programs. On a GAAP basis, Isis reported a loss from operations of $21.5 million and $57.8 million for the three and nine months ended September 30, 2014, respectively, compared to a loss from operations of $25.5 million and $31.8 million for the three and nine months ended September 30, 2013. Isis ended the third quarter with $592 million in cash, compared to $657 million at December 31, 2013.
ISIS: 46.34 (+1.75)
Isis Pharmaceuticals earns USD10m milestone payment for advancement of antisense drug ISIS-BIIB3 Rx
M2 - Fri Nov 07, 6:22AM CST
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Thursday that it expects to receive USD10m milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx.
BIIB: 325.92 (+5.17), ISIS: 46.34 (+1.75)
All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 2:17PM CST
Isis Pharmaceuticals releases earnings on Friday, but don't expect the company to give investors much information about the launch of its approved drug, Kynamaro. The drug is sold by Isis' marketing partner Sanofi , which doesn't break out sales...
ISIS: 46.34 (+1.75), SNY: 46.26 (+0.57)
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
PR Newswire - Thu Nov 06, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
BIIB: 325.92 (+5.17), ISIS: 46.34 (+1.75)
Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:00PM CST
Isis Pharmaceuticals (ISIS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 7.
MNK: 92.88 (+1.82), BDSI: 16.33 (+0.83), ISIS: 46.34 (+1.75), GSK: 45.18 (+0.27)
Why ISIS Pharmaceuticals, Inc. Catapulted 19% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 8:15AM CST
ISIS data by YCharts What: Shares of ISIS Pharmaceuticals , a biopharmaceutical company using its proprietary antisense technology platform to develop therapies across a wide range of diseases, catapulted higher by 19% in October, based on...
ISIS: 46.34 (+1.75), GSK: 45.18 (+0.27)
Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca
PR Newswire - Wed Nov 05, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7.5 million milestone payment, the first of two milestone payments totaling $15 million, from AstraZeneca for the advancement of ISIS-STAT3Rx, also referred to as AZD9150, in patients with advanced cancers. Isis will earn the second $7.5 million milestone payment from AstraZeneca upon initiation of a Phase 2 study. Isis has completed a clinical study of ISIS-STAT3Rx in patients with advanced cancers and plans to present results from this study at an upcoming medical meeting. AstraZeneca is currently evaluating ISIS-STAT3Rx in a Phase 1/2 clinical study in patients with advanced metastatic liver cancer. AstraZeneca plans to initiate additional clinical studies to further evaluate ISIS-STAT3Rx.
ISIS: 46.34 (+1.75)
Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Mon Nov 03, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the closing of its previously announced underwritten public offering of $103.5 million of shares of its common stock, including $13.5 million of shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $17.00 per share. Of the total 6,088,235 shares sold in the offering, 4,808,824 shares were sold by Regulus and 1,279,411 shares were sold by an existing stockholder of Regulus, Isis Pharmaceuticals, Inc. (NASDAQ:ISIS). The net proceeds to Regulus from the offering are expected to be approximately $76.1 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Regulus. Regulus will not receive any proceeds from the sale of shares by Isis.
ISIS: 46.34 (+1.75), DB: 29.95 (-0.29), RGLS: 22.82 (+0.74)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 87.00 (+3.09), ISIS: 46.34 (+1.75), SGEN: 35.68 (-0.37), GILD: 107.17 (+0.72), SSYS: 104.73 (+1.66), HP: 86.97 (+0.27), REGN: 383.12 (+5.28), CELG: 107.75 (+1.30)
Isis Pharmaceuticals Earns $5 Million in Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx
PR Newswire - Mon Nov 03, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GSK related to the designation of ISIS-GSK5Rx as a development candidate. ISIS-GSK5Rx is an antisense drug designed to treat an undisclosed ocular disease.
ISIS: 46.34 (+1.75)
Isis Pharmaceuticals Shares Up 40.9% Since SmarTrend's Buy Recommendation (ISIS)
Comtex SmarTrend(R) - Fri Oct 31, 10:59AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 40.92% as of today's recent price of $46.68.
ISIS: 46.34 (+1.75)
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 3.11 (-0.03), ACAD: 28.10 (+0.41), HALO: 9.10 (-0.02), ISIS: 46.34 (+1.75), NSPH: 0.41 (-0.01)
Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call
PR Newswire - Fri Oct 31, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
ISIS: 46.34 (+1.75)
Critical Alerts For AT&T, SolarWinds, Whole Foods Market, FireEye and Isis Pharmaceuticals Released By InvestorsObserver
PR Newswire - Thu Oct 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for T, SWI, WFM, FEYE and ISIS.
WFM: 47.65 (+0.84), T: 35.07 (+0.16), SWI: 48.31 (unch), FEYE: 32.46 (+1.84), ISIS: 46.34 (+1.75)
Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference
PR Newswire - Thu Oct 30, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 8:30 a.m. ET in Boston, MA.
ISIS: 46.34 (+1.75)
'Mad Money' Lightning Round: Stay Away From Applied Materials
at The Street - Thu Oct 30, 5:00AM CDT
Cramer prefers Isis Pharmaceuticals to Pfizer and Kinder Morgan to El Paso Pipeline Partners.
KMI: 38.53 (-0.22), EPB: 40.77 (-0.14), ISIS: 46.34 (+1.75), PFE: 30.24 (+0.32), AMAT: 22.66 (+0.23), INVN: 15.14 (-0.06), IGT: 16.50 (+0.13), REGN: 383.12 (+5.28), CVRR: 23.01 (-0.80), CELG: 107.78 (+1.33)
Recent News posted below.
Isis Pharmaceuticals ISIS other info.
http://investorshangout.com/Isis-Pharmaceuticals-ISIS-54504/
ISIS Isis Pharmaceuticals Recent Headline News
34.6% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Fri Nov 07, 4:40PM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 34.61% as of today's recent price of $44.59.
ISIS: 46.34 (+1.75)
Look for Shares of Isis Pharmaceuticals to Potentially Rebound after Yesterday's 1.46% Sell Off
Comtex SmarTrend(R) - Fri Nov 07, 4:09PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $42.06 to a high of $44.93. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $43.87 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ISIS: 46.34 (+1.75)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 325.92 (+5.17), ALNY: 98.81 (+2.97), ISIS: 46.34 (+1.75), OGXI: 2.18 (unch), TEVA: 58.04 (+0.34), RGLS: 22.80 (+0.72), GSK: 45.18 (+0.27), SNY: 46.26 (+0.57)
Isis beats 3Q profit forecasts
Automated Insights - Fri Nov 07, 7:48AM CST
CARLSBAD, Calif. (AP) _ Isis Pharmaceuticals Inc. (ISIS) on Friday reported a third-quarter loss of $26.7 million.
ISIS: 46.34 (+1.75)
Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
PR Newswire - Fri Nov 07, 7:30AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $13.4 million and $34.9 million for the three and nine months ended September 30, 2014, respectively, compared to an NOL of $22.7 million and $23.5 million for the same periods in 2013. Isis' revenue increased by more than 20% during the first nine months of 2014 compared to 2013 primarily due to the successes of its partnered programs as they advanced through research and development. In addition to the increase in revenue, Isis had a planned increase in operating expenses primarily associated with its late-stage clinical programs. On a GAAP basis, Isis reported a loss from operations of $21.5 million and $57.8 million for the three and nine months ended September 30, 2014, respectively, compared to a loss from operations of $25.5 million and $31.8 million for the three and nine months ended September 30, 2013. Isis ended the third quarter with $592 million in cash, compared to $657 million at December 31, 2013.
ISIS: 46.34 (+1.75)
Isis Pharmaceuticals earns USD10m milestone payment for advancement of antisense drug ISIS-BIIB3 Rx
M2 - Fri Nov 07, 6:22AM CST
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Thursday that it expects to receive USD10m milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx.
BIIB: 325.92 (+5.17), ISIS: 46.34 (+1.75)
All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 2:17PM CST
Isis Pharmaceuticals releases earnings on Friday, but don't expect the company to give investors much information about the launch of its approved drug, Kynamaro. The drug is sold by Isis' marketing partner Sanofi , which doesn't break out sales...
ISIS: 46.34 (+1.75), SNY: 46.26 (+0.57)
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
PR Newswire - Thu Nov 06, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
BIIB: 325.92 (+5.17), ISIS: 46.34 (+1.75)
Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:00PM CST
Isis Pharmaceuticals (ISIS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 7.
MNK: 92.88 (+1.82), BDSI: 16.33 (+0.83), ISIS: 46.34 (+1.75), GSK: 45.18 (+0.27)
Why ISIS Pharmaceuticals, Inc. Catapulted 19% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 8:15AM CST
ISIS data by YCharts What: Shares of ISIS Pharmaceuticals , a biopharmaceutical company using its proprietary antisense technology platform to develop therapies across a wide range of diseases, catapulted higher by 19% in October, based on...
ISIS: 46.34 (+1.75), GSK: 45.18 (+0.27)
Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca
PR Newswire - Wed Nov 05, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7.5 million milestone payment, the first of two milestone payments totaling $15 million, from AstraZeneca for the advancement of ISIS-STAT3Rx, also referred to as AZD9150, in patients with advanced cancers. Isis will earn the second $7.5 million milestone payment from AstraZeneca upon initiation of a Phase 2 study. Isis has completed a clinical study of ISIS-STAT3Rx in patients with advanced cancers and plans to present results from this study at an upcoming medical meeting. AstraZeneca is currently evaluating ISIS-STAT3Rx in a Phase 1/2 clinical study in patients with advanced metastatic liver cancer. AstraZeneca plans to initiate additional clinical studies to further evaluate ISIS-STAT3Rx.
ISIS: 46.34 (+1.75)
Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Mon Nov 03, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the closing of its previously announced underwritten public offering of $103.5 million of shares of its common stock, including $13.5 million of shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $17.00 per share. Of the total 6,088,235 shares sold in the offering, 4,808,824 shares were sold by Regulus and 1,279,411 shares were sold by an existing stockholder of Regulus, Isis Pharmaceuticals, Inc. (NASDAQ:ISIS). The net proceeds to Regulus from the offering are expected to be approximately $76.1 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Regulus. Regulus will not receive any proceeds from the sale of shares by Isis.
ISIS: 46.34 (+1.75), DB: 29.95 (-0.29), RGLS: 22.82 (+0.74)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 87.00 (+3.09), ISIS: 46.34 (+1.75), SGEN: 35.68 (-0.37), GILD: 107.17 (+0.72), SSYS: 104.73 (+1.66), HP: 86.97 (+0.27), REGN: 383.12 (+5.28), CELG: 107.75 (+1.30)
Isis Pharmaceuticals Earns $5 Million in Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx
PR Newswire - Mon Nov 03, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GSK related to the designation of ISIS-GSK5Rx as a development candidate. ISIS-GSK5Rx is an antisense drug designed to treat an undisclosed ocular disease.
ISIS: 46.34 (+1.75)
Isis Pharmaceuticals Shares Up 40.9% Since SmarTrend's Buy Recommendation (ISIS)
Comtex SmarTrend(R) - Fri Oct 31, 10:59AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 40.92% as of today's recent price of $46.68.
ISIS: 46.34 (+1.75)
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 3.11 (-0.03), ACAD: 28.10 (+0.41), HALO: 9.10 (-0.02), ISIS: 46.34 (+1.75), NSPH: 0.41 (-0.01)
Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call
PR Newswire - Fri Oct 31, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
ISIS: 46.34 (+1.75)
Critical Alerts For AT&T, SolarWinds, Whole Foods Market, FireEye and Isis Pharmaceuticals Released By InvestorsObserver
PR Newswire - Thu Oct 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for T, SWI, WFM, FEYE and ISIS.
WFM: 47.65 (+0.84), T: 35.07 (+0.16), SWI: 48.31 (unch), FEYE: 32.46 (+1.84), ISIS: 46.34 (+1.75)
Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference
PR Newswire - Thu Oct 30, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 8:30 a.m. ET in Boston, MA.
ISIS: 46.34 (+1.75)
'Mad Money' Lightning Round: Stay Away From Applied Materials
at The Street - Thu Oct 30, 5:00AM CDT
Cramer prefers Isis Pharmaceuticals to Pfizer and Kinder Morgan to El Paso Pipeline Partners.
KMI: 38.53 (-0.22), EPB: 40.77 (-0.14), ISIS: 46.34 (+1.75), PFE: 30.24 (+0.32), AMAT: 22.66 (+0.23), INVN: 15.14 (-0.06), IGT: 16.50 (+0.13), REGN: 383.12 (+5.28), CVRR: 23.01 (-0.80), CELG: 107.78 (+1.33)
(0)
(0)Ionis Pharmaceuticals, Inc. (IONS) Stock Research Links
Scroll down for more posts ▼